论文部分内容阅读
目的探讨不同阶段T2DM患者循环miRNA-126水平变化及与内皮型一氧化氮合酶(eNOS)及相关代谢指标的关系。方法采用RT-PCR检测血浆miRNA-126表达水平,ELISA测定eNOS水平,分析miRNA-126与eNOS及相关代谢指标的关系。结果 (1)与健康对照(NGT)组比较,miRNA-126在T2DM前期(Pre-T2DM)组、单纯T2DM(T2DM)组及T2DM合并大血管病变(T2DM+CVD)组中均下降(P<0.05)。(2)miRNA-126与LDL-C、DBP及eNOS呈正相关(r=0.224、0.164、0.661,P均<0.05),与FPG、HDL-C、HbA1c及年龄呈负相关(r=-0.293、-0.153、-0.258、-0.277,P均<0.05)。(3)多元逐步回归分析显示,FPG(β=-0.159,P<0.01)、年龄(β=-0.030,P<0.01)、LDL-C(β=0.208,P=0.037)、eNOS(β=0.353,P<0.01)是循环miRNA-126的影响因素。结论循环miRNA-126在不同阶段T2DM患者中均呈低表达,FPG、年龄、LDL-C及eNOS是影响miRNA-126的相关因素,推测miRNA-126可能受糖脂代谢的调控,其下调可能与血管内皮功能障碍有关。
Objective To investigate the relationship between circulating miRNA-126 levels and endothelial nitric oxide synthase (eNOS) and related metabolic parameters in T2DM patients at different stages. Methods The plasma level of miRNA-126 was detected by RT-PCR. The eNOS level was measured by ELISA. The relationship between miRNA-126 and eNOS and related metabolic parameters was analyzed. Results (1) Compared with healthy controls (NGT), miRNA-126 decreased in pre-T2DM group, T2DM group and T2DM + CVD group (P < 0.05). (2) There was a positive correlation between miRNA-126 and LDL-C, DBP and eNOS (r = 0.224,0.164,0.661, P <0.05) and negative correlation with FPG, HDL-C and HbA1c -0.153, -0.258, -0.277, P <0.05). (3) The multiple stepwise regression analysis showed that there was no significant difference between the groups of FPG (β = -0.159, P <0.01), age (β = -0.030, P <0.01), LDL-C 0.353, P <0.01) were the influencing factors of circulating miRNA-126. Conclusions Circulating miRNA-126 is low expressed in different stages of T2DM patients. FPG, age, LDL-C and eNOS are the related factors affecting miRNA-126. It is speculated that miRNA-126 may be regulated by glucose and lipid metabolism, Vascular endothelial dysfunction.